Cansino Biologics, Inc. Class ASSE: 688185

Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

· Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis

Earlier from Cansino Biologics, Inc. Class A

All Cansino Biologics, Inc. Class A news releases